Where Will Iovance Biotherapeutics Stock Be in 5 Years?
There's a lot of excitement around Iovance Biotherapeutics (NASDAQ: IOVA) as its shares are up over 40% year-to-date. Investors and analysts both see even more upside for this mid-cap biotech stock in the long run. Today, however, the company remains deeply unprofitable, only recently obtaining approval from regulators for one of its treatments.
Below, I'll look at what the business may look like five years from now, whether it could be profitable, and if it's worth investing in the stock today.
Iovance investors got great news in February when the Food and Drug Administration approved Amtagvi (lifileucel), the company's cell therapy for unresectable or metastatic melanoma. It's an important milestone for the business to have an approved treatment in its portfolio, and there could be more to come for Iovance.
Source Fool.com
